Combination therapy for advanced colorectal cancer liver tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have colorectal cancer that has spread to the liver and cannot be removed with surgery
- You have not had any previous treatment (like chemotherapy or targeted therapy) for these liver metastases
- You are physically active and able to care for yourself (ECOG 0-1)
- You have adequate liver, kidney, and blood function
- You have a type of tumor that is mismatch-repair proficient (pMMR) or microsatellite stable (MSS)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (retlirafusp alfa) combined with two chemotherapy drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has spread to the liver and has a specific gene change (RAS mutation). It aims to see if this combination can shrink tumors and improve outcomes in people who have not had prior treatment.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus another drug (Bevacizumab) and chemotherapy (CAPEOX) for people with colorectal cancer that has spread to the liver. The goal is to shrink the tumors enough to allow surgery to remove them.
This trial tests a new combination of drugs (Retlirafusp Alfa, Bevacizumab, and chemotherapy) with or without a short course of radiation for people with colorectal cancer that has spread only to the liver and who have not had any prior treatment. The goal is to see if this approach is safe and effective.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial is testing a combination of a new immunotherapy drug (QL1706) with chemotherapy and either cetuximab or bevacizumab for people with colorectal cancer that has spread to the liver and can potentially be removed by surgery. The goal is to shrink the tumors before surgery, making them easier to remove.
This trial tests a combination of treatments for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It uses an oncolytic virus (which infects and kills cancer cells) along with radiation, chemotherapy, targeted therapy, and immunotherapy to try to shrink the liver tumors.
Hear when a new Colorectal Adenocarcinoma Metastatic in the Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.